Shire Kills Momenta Biosim Deal

Shire has terminated its collaboration with Momenta Pharma to develop and commercialize a Humira biosimilar
Sept. 28, 2016

Shire has terminated its collaboration with Momenta Pharma to develop and commercialize a Humira biosimilar.

At the start of 2016, UK-based Shire struck a $32 bn deal to acquire U.S. rival, Baxalta. The collaboration between Baxalta and Momenta to develop and commercialize M923, a proposed Humira biosimilar, met a primary endpoint in December 2015.  

As part of the Shire-Baxalta deal, Shire sought to achieve double-digit revenue growth with total revenue to exceed $20 billion by 2020. According to Momenta, Shire terminated the partnership “based on a comprehensive portfolio assessment.” 

Shire will now begin to work to transfer all ongoing clinical, regulatory and commercialization activities for M923 to Momenta.

Read the BBC news coverage

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates